Back to top
more

Coherus BioSciences (CHRS)

(Delayed Data from NSDQ)

$2.04 USD

2.04
907,173

+0.11 (5.70%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CHRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Coherus BioSciences, Inc. [CHRS]

Reports for Purchase

Showing records 1 - 20 ( 68 total )

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/20/2024

Company Report

Pages: 4

Model Update Post 4Q; Adjusting Price Target to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/14/2024

Daily Note

Pages: 3

4Q First Impressions: Moving Forward to Profitability in 2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/22/2024

Daily Note

Pages: 3

Coherus Refines Its Focus Even Further; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

01/19/2024

Daily Note

Pages: 3

More Good News From Casdozo For Coherus; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/11/2024

Daily Note

Pages: 4

Heading Into 2024 Moving in the Right Direction; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/27/2023

Daily Note

Pages: 3

On-Body Gives Coherus a Boost into the New Year; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

12/07/2023

Daily Note

Pages: 3

Encouraging Initial Data For Casdozo; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/07/2023

Company Report

Pages: 5

Outlook Lowered, But Foundation for 2024 Looks Solid; Price Target Down to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/30/2023

Daily Note

Pages: 3

Tori Gets Across the Finish Line; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/06/2023

Daily Note

Pages: 3

That Was Fast... Udenyca On-Body BLA Refiled and Approval by Year-End is In Sight

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

09/26/2023

Daily Note

Pages: 3

Need to Wait For the On-Body; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/24/2023

Industry Report

Pages: 6

Perspectives on the Cost-Effectiveness of Treating wet AMD

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/03/2023

Company Report

Pages: 5

Revenues Resume Upward Trend; Adjusting PT to $20; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

07/18/2023

Daily Note

Pages: 6

Takeaways From Our Conversation With Coherus BioSciencesÂ’ Management; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

06/20/2023

Daily Note

Pages: 5

No Slowing Down for Coherus

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

06/06/2023

Daily Note

Pages: 4

Coherus Showcases Clinical Benefit of Toripalimab at ASCO 2023; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

06/06/2023

Industry Report

Pages: 4

Emerging Ideas in Biopharma Call Series

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

06/02/2023

Daily Note

Pages: 3

Stirring the Pot as Coherus Sets Low Price for Yusimry on the Cusp of Market Formation for Humira Biosimilars

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

06/01/2023

Daily Note

Pages: 3

Toripalimab Takes a Big Step Towards Approval

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Coherus BioSciences, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

05/09/2023

Company Report

Pages: 5

Things Should Start to Turn; Adjusting PT to $24; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party